Zhang Kaiping, Zhang Li, Zhou Jun, Hao Zongyao, Fan Song, Yang Cheng, Liang Chaozhao
Department of Urology, The First Affiliated Hospital of Anhui Medical University and Institute of Urology, Anhui Medical University, Hefei, Anhui, People's Republic of China.
Onco Targets Ther. 2016 Jan 27;9:567-77. doi: 10.2147/OTT.S94348. eCollection 2016.
Interleukin-6 (IL-6) is a multifunctional proinflammatory cytokine involved in cancer initiation and progression. Numerous studies have investigated the associations between IL-6 polymorphisms (IL-6 -174G>C, -592G>C, -597G>A) and risk of urinary system cancers, including prostate cancer, bladder cancer, and renal cell cancer. However, conclusions from these studies were controversial. Thus, we conducted the current meta-analysis to obtain the comprehensive profile regarding the association between IL-6 polymorphisms and urinary system cancer risk.
According to inclusion and exclusion criteria, the associations of IL-6 polymorphisms with urinary system cancer were searched from database and analyzed using STATA 12.0 statistical software. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the associations.
A total of 20 previous publications consisting of 15,033 cases and 17,655 controls were involved in this meta-analysis. Significant association was observed in overall population regarding IL-6 -592G>C polymorphisms (G vs C: OR =0.1.30, 95% CI =1.13-2.52; GG vs CC: OR =1.81, 95% CI =1.31-2.52; GG vs GC + CC: OR =1.33, 95% CI =1.02-1.75; GG + GC vs CC: OR =1.41, 95% CI =1.09-1.83). In the stratified analyses by ethnicity, the significant associations were found among Asian (GG vs CC: OR =1.89, 95% CI =1.34-2.66; GG + GC vs CC: OR =1.43, 95% CI =1.09-1.87) and Black population (GC vs CC: OR =0.20, 95% CI =0.05-0.82) rather than Caucasian men. Likewise, there were noticeable associations in almost all the other subanalyses such as cancer types, control sources, genotyped methods, and sample sizes. However, no significant associations were identified between any of IL-6 -174G>C polymorphisms with urinary system cancer, except for Asian population (G vs C: OR =0.81, 95% CI =0.70-0.95; GG vs CC: OR =0.51, 95% CI =0.35-0.74; GC vs CC: OR =0.49, 95% CI =0.33-0.72; GG + GC vs CC: OR =0.50, 95% CI =0.35-0.72; respectively). In addition, no significant associations were detected between IL-6 -597G>A polymorphism and urinary system cancer, regardless of whole or subgroups.
This meta-analysis presents a relatively comprehensive view of the associations between IL-6 polymorphism and urinary system cancer risk to explore the carcinogenic mechanisms, which will help shed light on the clinical diagnosis and therapy for urinary system cancer. However, further detailed studies are needed to verify our conclusion.
白细胞介素-6（IL-6）是一种多功能促炎细胞因子，参与癌症的发生和发展。众多研究调查了IL-6基因多态性（IL-6 -174G>C、-592G>C、-597G>A）与泌尿系统癌症风险之间的关联，包括前列腺癌、膀胱癌和肾细胞癌。然而，这些研究的结论存在争议。因此，我们进行了当前的荟萃分析，以获得关于IL-6基因多态性与泌尿系统癌症风险之间关联的全面概况。
根据纳入和排除标准，从数据库中检索IL-6基因多态性与泌尿系统癌症的关联，并使用STATA 12.0统计软件进行分析。采用比值比（OR）及95%置信区间（CI）评估关联强度。
本荟萃分析共纳入20篇先前发表的文献，包括15,033例病例和17,655例对照。在总体人群中，观察到IL-6 -592G>C基因多态性存在显著关联（G与C比较：OR =1.30，95%CI =1.13 - 2.52；GG与CC比较：OR =1.81，95%CI =1.31 - 2.52；GG与GC + CC比较：OR =1.33，95%CI =1.02 - 1.75；GG + GC与CC比较：OR =1.41，95%CI =1.09 - 1.83）。在按种族进行的分层分析中，亚洲人群（GG与CC比较：OR =1.89，95%CI =1.34 - 2.66；GG + GC与CC比较：OR =1.43，95%CI =1.09 - 1.87）和黑人人群（GC与CC比较：OR =0.20，95%CI =0.05 - 0.82）中发现了显著关联，而白人男性中未发现。同样，在几乎所有其他亚组分析中，如癌症类型、对照来源、基因分型方法和样本量等，也存在明显关联。然而，除亚洲人群外（G与C比较：OR =0.81，95%CI =0.70 - 0.95；GG与CC比较：OR =0.51，95%CI =0.35 - 0.74；GC与CC比较：OR =0.49，95%CI =0.33 - 0.72；GG + GC与CC比较：OR =0.50，95%CI =0.35 - 0.72），未发现IL-6 -174G>C基因多态性与泌尿系统癌症之间存在显著关联。此外，无论总体还是亚组分析，均未检测到IL-6 -597G>A基因多态性与泌尿系统癌症之间存在显著关联。
本荟萃分析对IL-6基因多态性与泌尿系统癌症风险之间的关联提供了相对全面的观点，有助于探索致癌机制，这将为泌尿系统癌症的临床诊断和治疗提供参考。然而，需要进一步详细研究来验证我们的结论。
